Management of the hormonal syndrome of neuroendocrine tumors

• Published in: Archives of medical science Vol. 13; no. 3; pp. 515 - 524
• Main Authors: Gut, Paweł, Waligórska-Stachura, Joanna, Czarnywojtek, Agata, Sawicka-Gutaj, Nadia, Bączyk, Maciej, Ziemnicka, Katarzyna, Fischbach, Jakub, Woliński, Kosma, Kaznowski, Jarosław, Wrotkowska, Elżbieta, Ruchała, Marek
• Format: Journal Article
• Language: English
• Published: Poland Termedia Publishing House 01.04.2017
• Subjects: hormonal syndrome; Insulin; Neuroendocrine tumors; Pancreatic cancer; State of the Art Paper; hormonal syndrome; neuroendocrine tumors
• ISSN: 1734-1922; 1896-9151
• DOI: 10.5114/aoms.2016.60311

Gastroenteropancreatic neuroendocrine tumors (GEP/NET) are unusual and rare neoplasms that present many clinical challenges. They characteristically synthesize store and secrete a variety of peptides and neuroamines which can lead to the development of distinct clinical syndrome, however many are clinically silent until late presentation with mass effects. Management strategies include surgery cure and cytoreduction with the use of somatostatin analogues. Somatostatin have a broad range of biological actions that include inhibition of exocrine and endocrine secretions, gut motility, cell proliferation, cell survival and angiogenesis. Five somatostatin receptors (SSTR1-SSTR5) have been cloned and characterized. Somatostatin analogues include octreotide and lanreotide are effective medical tools in the treatment and present selectivity for SSTR2 and SSTR5. During treatment is seen disapperance of flushing, normalization of bowel movements and reduction of serotonin and 5-hydroxyindole acetic acid (5-HIAA) secretion. Telotristat represents a novel approach by specifically inhibiting serotonin synthesis and as such, is a promising potential new treatment for patients with carcinoid syndrome. To pancreatic functionig neuroendocrine tumors belongs insulinoma, gastrinoma, glucagonoma and VIP-oma. Medical management in patients with insulinoma include diazoxide which suppresses insulin release. Also mTOR inhibitors may inhibit insulin secretion. Treatment of gastrinoma include both proton pump inhibitors (PPIs) and histamine H2 - receptor antagonists. In patients with glucagonomas hyperglycaemia can be controlled using insulin and oral blood glucose lowering drugs. In malignant glucagonomas smatostatin analogues are effective in controlling necrolytic migratory erythemia. Severe cases of the VIP-oma syndrome require supplementation of fluid losses. Octreotide reduce tumoral VIP secretion and control secretory diarrhoea.